Jared Whitlock

Reporter

Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

Antibiotic Developer Forge Therapeutics Inks Licensing Deal

Forge Therapeutics will license its platform to Basilea Pharmaceutica to create new antibiotics, it was announced April 24.

Funding Puts EvoFem in Position for Product Launch

Through a private stock placement Evofem Biosciences raised $30 million and said a second tranche is expected to provide up to $50 million more as the company gets closer to asking for regulatory approval of its birth control gel.

Avidity Biosciences Bags $35M Upfront from Eli Lilly

La Jolla’s Avidity Biosciences will receive $35 million upfront and potentially much more through a deal with Eli Lilly.

Scripps Launches Clinic for Inflammatory Breast Cancer

A clinic to diagnose, treat and monitor a rare form of breast cancer has launched at Scripps MD Anderson Cancer Center.

Poseida Therapeutics Raises $142M for Cancer Cell Therapy

Poseida is working to advance CAR-T therapy, in which a patient’s T cells are altered to kill cancer cells. The San Diego company developed what are called stem memory T cells. They aim to be safer — and last much longer — than early CAR-T products.

ECONOMY: San Diego Is a Clear Winner as Qualcomm's Stock Surges

The end of a royalty dispute that bogged down Qualcomm Inc., one of San Diego’s largest employers, looks to be a win for the region.

Tease photo

• AirporTour, a San Diego-based company that is building interactive airport guides with audio tours. • Ciari Guitars Inc., a San Diego-based startup that makes foldable travel guitars. The company p

A division of Rady Children’s Hospital that deploys quick-turnaround genomic sequencing in puzzling cases has added six board members.

Tease photo

PhaseBio Drug Receives ‘Breakthrough’ Designation

PhaseBio’s drug that aims to stop bleeding events received a breakthrough drug designation from the U.S. Food and Drug Administration. That follows an initial public offering and promising test results.

Tease photo

Salk Institute Receives $35M for Plant Initiative Fighting Climate Change

The Salk Institute for Biological Studies is set to receive $35 million to develop plants that suck up large amounts of carbon from the atmosphere to fight climate change.

Turning Point Therapeutics Raises $166.5M in Public Debut

Cancer drug developer Turning Point Therapeutics raised $166.5 million in its public market debut, an amount that surpassed original company expectation.

Viracta Therapeutics Receives Orphan Drug Designation

Viracta Therapeutics will receive tax credits and other benefits under a recent orphan drug designation, the latest from a company that’s been in the news lately.

PhaseBio Drug Garners Breakthrough Designation

PhaseBio’s drug that aims to stop bleeding events received a breakthrough drug designation from the U.S. Food and Drug Administration.

Rady Children’s Institute for Genomic Medicine Adds 6 Board Members

A division of Rady Children’s Hospital that deploys quick-turnaround genomic sequencing in puzzling cases has added six board members.

MedImpact Announces Layoffs

San Diego-based MedImpact Healthcare Systems will lay off up to 64 employees, citing business consolidation.

Tease photo

Turning Point Therapeutics Lays Out Terms for $125M IPO

Turning Point Therapeutics — which is developing drugs for treatment-resistant cancers — set terms for an initial public offering.

Sorrento Therapeutics Files Lawsuit Against Soon-Shiong

San Diego’s Sorrento Therapeutics has accused biotech entrepreneur Patrick Soon-Shiong of a “catch and kill” scheme to keep a drug off the market, according to a complaint filed in Los Angeles Superior Court.

Evofem Expects to Raise up to $80M in Private Stock Placement

Through a private stock placement Evofem Biosciences raised $30 million and said a second tranche is expected to provide up to $50 million more as the company gets closer to asking for regulatory approval of its birth control gel.

EDs Deal With Shortfalls In Mental Health Care

MEDICINE: Local Hospitals Try To Mitigate Stresses on System

An emergency department director with UC San Diego Health, Dr. Gary Vilke keeps a close eye on trends. One that leaps out: more patients in the throes of a mental health crisis.

Tease photo

MedImpact to Lay Off 64 Employees

San Diego-based MedImpact Healthcare Systems will lay off 64 employees, citing business consolidation.

Turning Point Therapeutics Lays Out Terms for $125M IPO

Turning Point Therapeutics — which is developing drugs for treatment-resistant cancers — set terms for an initial public offering.

SBP Partnering for Finding Promising New Drug Targets

To speed the drug discovery path, San Diego’s Sanford Burnham Prebys Medical Discovery Institute, or SBP, recently partnered with WARF Therapeutics.

Q1 Brings Welcome Change to San Diego Life Science Stocks

INVEST: Market Confidence Makes A Comeback

San Diego life science stocks largely recovered in the first quarter after taking a beating at the end of last year.

Tease photo

SD 500: Peter Zien

SD 500 recap: Peter Zien was instrumental in building the region’s craft brewing reputation.

Tease photo

CureMetrix’s Mammogram Software Wins FDA Approval

BIOTECH: Co. Employs Deep Learning, AI and Extensive Image Data

CureMetrix recently got the U.S. Food and Drug Administration’s blessing to market software that flags which mammograms raise suspicions of breast cancer.

Tease photo

Charles River Laboratories to Lay off 24, Close San Diego Site

Charles River Laboratories, among the firms playing niche roles in drug development, plans to close its San Diego site and lay off 24 employees.

Turning Point Therapeutics Planning $100M IPO

FINANCE: Platform Tackles Enzyme Mutations That Hinder Cancer Treatments

Drugmaker Turning Point Therapeutics — taking aim at drug-resistant cancers — recently filed paperwork calling for a $100 million initial public offering.

New CEO Appointed at Epic Sciences

Lloyd Sanders, previously with Myriad Genetics, has joined Epic Sciences as CEO.

Biolinq Raises $4.75M in Extended Series A

Biolinq hauled in another $4.75 million to bring its series A round to $15 million, the glucose monitoring company announced March 28.

Turning Point Therapeutics Seeks $100 Million in IPO

Cancer drugmaker Turning Point Therapeutics recently filed paperwork calling for a $100 million initial public offering.

New CEO Appointed at Epic Sciences

Lloyd Sanders, previously with Myriad Genetics, has joined Epic Sciences as CEO.

Cellular Treatments for Diabetes Get $80M

BIOTECH: ViaCyte Built Up IP, Absorbed Rivals

In 1998, researchers derived stem cells from human embryos for the first time. With the advance came the hope of curing Type 1 diabetes.

Tease photo

San Diego Co. Sees Increasing Demand for CBD Products

CV Sciences is cashing in on rising demand for cannabidiol, or CBD.

Tease photo

PhaseBio Stock Jumps Following Good Results in Early-Stage Clinical Trials

PHARMA: Drug Used to Reverse Antiplatelet Activity

PhaseBio’s stock jumped March 18 after the company’s lead drug candidate showed promise in an early-stage clinical study.

Tease photo

Sharp HealthCare Wins Hearst Prize for Palliative Care Program

A Sharp HealthCare program that delivers palliative care at home captured the 2019 Hearst Prize.

CureMetrix’s Mammogram Software Wins FDA Approval

CureMetrix got the U.S. Food and Drug Administration’s blessing to market software that flags which mammograms raise suspicions of breast cancer.

PhaseBio Shares Rise on Clinical Study Data

PhaseBio’s stock jumped March 18 after the San Diego-based company’s lead drug candidate showed promise in an early-stage clinical study.

Life Sciences Leasing Activity Finished Strong in Q4 of 2018

For San Diego life sciences the fourth quarter of 2018 was the strongest of the year from a leasing perspective.

Tease photo

Potential Blockbuster Drug Could Bring Windfall to Scripps

Scripps Research stands to gain a royalty windfall from a drug candidate that slows brain atrophy in patients with multiple sclerosis.

Tease photo

Biotech Investors Look For Red Flags and Green

Do you bet on the jockey or the horse?  That question kicked off a Feb. 27 investor panel at Biocom’s 9th Annual Global Life Science Partnering Conference. The query gets at whether investors prioritize a biotech’s science or the management team.

Tease photo

Neurocrine’s Rare Disease Drug Generates Positive Clinical Data

Interim clinical trial results were positive for a Neurocrine drug aimed at a rare genetic disorder affecting the adrenal glands, the company reported March 12.

Sanford Burnham Prebys Appoints 2 Trustees

Sanford Burnham Prebys Medical Discovery Institute recently appointed two new board trustees: Matt Browne and David Szekeres.

ResMed Acquires HB Healthcare

San Diego-based ResMed, maker of cloud-connected sleep and respiratory care devices, has acquired South Korean company HB Healthcare for an undisclosed amount.

Erasca Brings in Big Series A

Erasca, founded on the bold goal of developing a new generation of oncology drugs, raised an additional $22 million as part of a Series A round.

Tease photo

Analysts See Pluses in Gossamer Bio’s Six-Drug Pipeline, Stock

Two analyst teams who recently started covering Gossamer Bio see a promising future for the San Diego biotech.

Tease photo

Oncternal Therapeutics Merges with GTx

San Diego-based Oncternal Therapeutics entered into a merger agreement with Tennessee’s GTx, it was announced March 7.

Erasca Raises $22M in Series A Extension

Erasca, founded on the bold goal of developing a new generation of oncology drugs, raised an additional $22 million as part of a series A round.

Dexcom Restructuring to Result in 350 Layoffs

Dexcom will lay off 350 workers largely in San Diego and Arizona as part of a restructuring, a move disclosed along with fourth quarter earnings that showed strong topline growth.

Ionis and Spinout Strike $150M Deal With Novartis

Carlsbad-based Ionis Pharmaceuticals has landed yet another big payout.

Tease photo

FDA Commissioner to Depart

Scott Gottlieb, the commissioner of the U.S. Food and Drug Administration announced his resignation March 5.

California Life Sciences Association Expands Board

The California Life Sciences Association added three new board members, it was announced this week.

Prev